{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:55:14Z","timestamp":1793228114113,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xphs.2023.09.010","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T11:41:34Z","timestamp":1694864494000},"page":"735-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Survey on Handling and Administration of Therapeutic Protein Products in German and Swiss Hospitals"],"prefix":"10.1016","volume":"113","author":[{"given":"Maximilian","family":"Wozniewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Besheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-5676","authenticated-orcid":false,"given":"J\u00f6rg","family":"Huwyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-6795","authenticated-orcid":false,"given":"Hanns-Christian","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-1336","authenticated-orcid":false,"given":"Vincent","family":"Levet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad S.","family":"Sediq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"Mabs"},{"key":"10.1016\/j.xphs.2023.09.010_bib0002","unstructured":"U.S. Food & Drug Administration. Compounding and the FDA: Questions and Answers. Available from: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/compounding-and-fda-questions-and-answers#what. Accessed 10 May 2023"},{"key":"10.1016\/j.xphs.2023.09.010_bib0003","unstructured":"The United States Pharmacopeial Convention. United States Pharmacopeia General Chapter <797>Pharmaceutical Compounding \u2013 Sterile Preparations."},{"key":"10.1016\/j.xphs.2023.09.010_bib0004","unstructured":"Council of Europe. Resolution CM\/Res(2016)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients."},{"key":"10.1016\/j.xphs.2023.09.010_bib0005","unstructured":"Council of Europe. Resolution CM\/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use."},{"issue":"8","key":"10.1016\/j.xphs.2023.09.010_bib0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11095-020-02859-z","article-title":"Formulation and administration of biological medicinal products","volume":"37","author":"Kramer","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2023.09.010_bib0007","unstructured":"The United States Pharmacopeial Convention. United States Pharmacopeia General Chapter <800>Hazardous Drugs \u2013 Handling in Healthcare Settings."},{"key":"10.1016\/j.xphs.2023.09.010_bib0008","unstructured":"European Directorate for the quality of Medicines & HealthCare. European Pharmacopoeia General Monographs: Pharmaceutical Preparations (2619)."},{"key":"10.1016\/j.xphs.2023.09.010_bib0009","unstructured":"PIC\/S PE Guide to good practices for the preparation of medicinal products in healthcare establishments. Available from: http:\/\/www.gmp-compliance.org\/guidemgr\/files\/PICS\/PE-010-4-GUIDETO-GOOD-PRACTICES-1.pdf. Accessed 10 May 2023"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.010_bib0010","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.xphs.2021.09.043","article-title":"An intercompany perspective on compatibility and in-use stability studies to enable administration of biopharmaceutical drug products","volume":"111","author":"Kamen","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.09.010_bib0011","unstructured":"Bl\u00fcmel M, Liu J, de Jong I, et al. Current industry best practice on in-use stability and compatibility studies for biological products. J Pharm Sci."},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0012","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1078155217726160","article-title":"Survey of guidelines and current practices for safe handling of antineoplastic and other hazardous drugs used in 24 countries","volume":"25","author":"Mathias","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.xphs.2023.09.010_bib0013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1078155214559113","article-title":"A survey of manufacturing and handling practices for monoclonal antibodies by pharmacy, nursing and medical personnel","volume":"22","author":"Alexander","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.xphs.2023.09.010_bib0014","first-page":"riad008","article-title":"The handling of biopharmaceuticals used in home-based therapy for cancer patients","author":"Hardebol","year":"2023","journal-title":"Int J Pharmacy Pract"},{"issue":"6","key":"10.1016\/j.xphs.2023.09.010_bib0015","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.xphs.2017.02.029","article-title":"Potential issues with the handling of biologicals in a hospital","volume":"106","author":"Jiskoot","year":"2017","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2023.09.010_bib0016","article-title":"Evaluation of post-production handling practices of monoclonal antibodies throughout the world","volume":"4","author":"Fayek","year":"2021","journal-title":"Eur J Oncol Pharmacy"},{"key":"10.1016\/j.xphs.2023.09.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2023.05.003","article-title":"Examination of the protein drug supply chain in a Swedish university hospital: focus on handling risks and mitigation measures","author":"Mart\u00ednez","year":"2023","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2023.09.010_bib0018","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.xphs.2018.04.005","article-title":"Postproduction handling and administration of protein pharmaceuticals and potential instability issues","volume":"107","author":"Nejadnik","year":"2018","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","article-title":"Physicochemical stability of monoclonal antibodies: a review","volume":"109","author":"Le Basle","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.09.010_bib0020","first-page":"165","article-title":"Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings","year":"2004","journal-title":"NIOSH, Pub"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.010_bib0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11095-020-02784-1","article-title":"Evaluation of different quality-relevant aspects of closed system transfer devices (CSTDs)","volume":"37","author":"Besheer","year":"2020","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0022","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5731\/pdajpst.2018.008664","article-title":"A case study to address a gap in the device-to-vial interface stopper push-in by chemo spikes","volume":"73","author":"Zhao","year":"2019","journal-title":"PDA J Pharm Sci Technol"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0023","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41598-021-03780-0","article-title":"Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs)","volume":"12","author":"Sumikawa","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.xphs.2019.10.042","article-title":"Challenges of using closed system transfer devices with biological drug products: an industry perspective","volume":"109","author":"Sreedhara","year":"2020","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2023.09.010_bib0025","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.xphs.2021.12.020","article-title":"A systematic approach to evaluating closed system drug-transfer devices during drug product development","volume":"111","author":"Patke","year":"2022","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2023.09.010_bib0026","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.xphs.2020.07.031","article-title":"Determination of holdup volume and transient contact compatibility of closed system transfer devices for a reconstituted lyophilized drug product","volume":"109","author":"Kagdi","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.09.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2023.04.014","article-title":"Closed System Transfer Devices (CSTDs): understanding potential over-and under-dosing of liquid vial drug products and how to generally mitigate","author":"Lehermayr","year":"2023","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1078155217753890","article-title":"How can the use of closed system transfer devices to facilitate sharing of drug vials be optimised to achieve maximum cost savings?","volume":"25","author":"Gilbar","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.xphs.2023.09.010_bib0029","unstructured":"European Medicines Agency. Note for guidance on in-use stability testing of human medicinal product. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-use-stability-testing-human-medicinal-products_en.pdf. Accessed 10 May 2023"},{"key":"10.1016\/j.xphs.2023.09.010_bib0030","series-title":"Fachinformation Besponsa\u00ae","year":"2022"},{"key":"10.1016\/j.xphs.2023.09.010_bib0031","series-title":"Prescribing Information Herceptin","year":"2018"},{"key":"10.1016\/j.xphs.2023.09.010_bib0032","series-title":"Prescribing Information Bavencio","year":"2019"},{"key":"10.1016\/j.xphs.2023.09.010_bib0033","series-title":"Prescribing Information Cyramza","year":"2022"},{"key":"10.1016\/j.xphs.2023.09.010_bib0034","series-title":"Guidance: Pharmacy Compounding of Human Drug Products under Section 503A of the Federal Food, Drug, and Cosmetic Act","year":"2018"},{"issue":"3","key":"10.1016\/j.xphs.2023.09.010_bib0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11095-020-2763-8","article-title":"Photo-degradation of therapeutic proteins: mechanistic aspects","volume":"37","author":"Schoneich","year":"2020","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2023.09.010_bib0036","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1002\/jps.23717","article-title":"Implications of in-use photostability: proposed guidance for photostability testing and labeling to support the administration of photosensitive pharmaceutical products, part 1: drug products administered by injection","volume":"102","author":"Baertschi","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.09.010_bib0037","series-title":"A Review of the Oncology Under-Dosing Incident","author":"Thiessen","year":"2013"},{"issue":"3","key":"10.1016\/j.xphs.2023.09.010_bib0038","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1310\/hpj4903-221","article-title":"Understanding and managing intravenous container overfill; potential dose confusion","volume":"49","author":"Cohen","year":"2014","journal-title":"Hosp Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2023.09.010_bib0039","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.xphs.2016.02.027","article-title":"Evaluating the role of the air-solution interface on the mechanism of subvisible particle formation caused by mechanical agitation for an IgG1 mAb","volume":"105","author":"Ghazvini","year":"2016","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.010_bib0040","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.xphs.2022.01.016","article-title":"Effects of transportation of IV bags containing protein formulations via hospital pneumatic tube system: particle characterization by multiple methods","volume":"111","author":"Linkuviene","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.09.010_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.apergo.2021.103584","article-title":"Usability of smart infusion pumps: a heuristic evaluation","volume":"98","author":"Klarich","year":"2022","journal-title":"Appl Ergon"},{"issue":"10","key":"10.1016\/j.xphs.2023.09.010_bib0042","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/jps.23224","article-title":"Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags","volume":"101","author":"Kumru","year":"2012","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0043","article-title":"Do plasticized polyvinylchloride and polyurethane infusion sets promote infliximab adsorption?","volume":"5","author":"Chennell","year":"2020","journal-title":"Pharmac Technol Hosp Pharmacy"},{"issue":"9","key":"10.1016\/j.xphs.2023.09.010_bib0044","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1039\/c2sm07017k","article-title":"Importance of the dynamics of adsorption and of a transient interfacial stress on the formation of aggregates of IgG antibodies","volume":"8","author":"Rudiuk","year":"2012","journal-title":"Soft Matter"},{"issue":"10","key":"10.1016\/j.xphs.2023.09.010_bib0045","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.xphs.2017.05.028","article-title":"Protein adsorption to in-line filters of intravenous administration sets","volume":"106","author":"Besheer","year":"2017","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2023.09.010_bib0046","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-021-03112-1","article-title":"Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review","volume":"77","author":"Negrier","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.xphs.2023.09.010_bib0047","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12968\/bjon.2018.27.14.S4","article-title":"Non-flushing of IV administration sets: an under-recognised under-dosing risk","volume":"27","author":"Cooper","year":"2018","journal-title":"Br J Nurs"},{"key":"10.1016\/j.xphs.2023.09.010_bib0048","series-title":"Prescribing Information Blincyto","year":"2017"},{"key":"10.1016\/j.xphs.2023.09.010_bib0049","series-title":"Prescribing Information Libtayo","year":"2018"},{"issue":"6","key":"10.1016\/j.xphs.2023.09.010_bib0050","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/jps.22045","article-title":"Adsorption behavior of a surfactant and a monoclonal antibody to sterilizing-grade filters","volume":"99","author":"Mahler","year":"2010","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2023.09.010_bib0051","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.xphs.2021.06.022","article-title":"Assessing the Utility of In-Line Intravenous Infusion Filters","volume":"110","author":"Ayres","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.09.010_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6570","article-title":"Central venous catheters","volume":"347","author":"Smith","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.xphs.2023.09.010_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101709","article-title":"Critical drug loss induced by silicone and polyurethane implantable catheters in a simulated infusion setup with three model drugs","volume":"13","author":"Tokhadze","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2023.09.010_bib0054","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmbbm.2016.08.002","article-title":"Mechanic and surface properties of central-venous port catheters after removal: a comparison of polyurethane and silicon rubber materials","volume":"64","author":"Braun","year":"2016","journal-title":"J Mech Behav Biomed Mater"},{"key":"10.1016\/j.xphs.2023.09.010_bib0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.xphs.2023.09.010_bib0056","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"5","key":"10.1016\/j.xphs.2023.09.010_bib0057","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2146\/ajhp140098","article-title":"In-use physicochemical and microbiological stability of biological parenteral products","volume":"72","author":"Ricci","year":"2015","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.010_bib0058","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ejhpharm-2018-001723","article-title":"Council of Europe Resolution CM\/Res(2016)2: a major contribution to patient safety from reconstituted injectable medicines?","volume":"27","author":"Beaney","year":"2020","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.010_bib0059","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ejhpharm-2020-002559","article-title":"Pharmacy preparations and compounding","volume":"28","author":"van der Schors","year":"2021","journal-title":"Eur J Hosp Pharmacy"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.010_bib0060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/10781552211010928","article-title":"Closed-system transfer device use with oncology biologics: a survey of Canadian healthcare practitioners","volume":"28","author":"Khaira","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0061","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.xphs.2019.07.021","article-title":"Overcoming challenges of implementing closed system transfer device clinical in-use compatibility testing for drug development of antibody drug conjugates","volume":"109","author":"Petoskey","year":"2020","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2023.09.010_bib0062","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.xphs.2021.02.008","article-title":"An industry perspective on the challenges of using closed system transfer devices with biologics and communication guidance to healthcare professionals","volume":"110","author":"Gopalrathnam","year":"2021","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2023.09.010_bib0063","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.xphs.2020.10.047","article-title":"An Industry perspective on compatibility assessment of closed system drug-transfer devices for biologics","volume":"110","author":"Besheer","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.09.010_bib0064","series-title":"Pharmacopoea Helvetica 17.1 Allgemeine Anforderungen an die Herstellung von Formula-Arzneimitteln","year":"2022"},{"key":"10.1016\/j.xphs.2023.09.010_bib0065","series-title":"Epidemiologisches Bulletin: Zu spezifischen Fragen bez\u00fcglich Rekonstitution, Zubereitung und Applikation von Arzneimitteln und Infusionsl\u00f6sungen sowie zur Hautantiseptik","year":"2016"},{"key":"10.1016\/j.xphs.2023.09.010_bib0066","article-title":"Preventing drug vial wastage and reducing expenditure associated with injectable cancer drugs: International oncology pharmacy survey","author":"Gilbar","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.xphs.2023.09.010_bib0067","article-title":"Review of studies examining microbial contamination of vials used for preparations done with closed-system drug transfer devices","author":"Soubieux","year":"2019","journal-title":"Eur J Hosp Pharmacy"},{"key":"10.1016\/j.xphs.2023.09.010_bib0068","unstructured":"ICH. Photostability Testing of New Active Substances and Medicinal Products."},{"key":"10.1016\/j.xphs.2023.09.010_bib0069","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2015.12.003","article-title":"Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development","volume":"100","author":"Sreedhara","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2023.09.010_bib0070","series-title":"Prescribing Information Darzalex","year":"2015"},{"issue":"4","key":"10.1016\/j.xphs.2023.09.010_bib0071","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ejhpharm-2011-000048","article-title":"Comparison of container system residual volumes and the implications for medication error","volume":"19","author":"Lannoy","year":"2012","journal-title":"Eur J Hosp Pharmacy"},{"key":"10.1016\/j.xphs.2023.09.010_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmbbm.2022.105477","article-title":"Impact of mechanical stress on flexible tubing used for biomedical applications: characterization of the damages and impact on the patient's health","author":"Saunier","year":"2022","journal-title":"J Mech Behav Biomed Mater"},{"issue":"2","key":"10.1016\/j.xphs.2023.09.010_bib0073","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijpharm.2015.10.082","article-title":"Particle contamination of parenteralia and in-line filtration of proteinaceous drugs","volume":"496","author":"Werner","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2023.09.010_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123091","article-title":"Comparative study between a gravity-based and peristaltic pump for intravenous infusion with respect to generation of proteinaceous microparticles","author":"Hada","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2023.09.010_bib0075","series-title":"Fachinformation Sterofundin ISO Infusionsl\u00f6sung","author":"Braun","year":"2014"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0076","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12913-018-3025-x","article-title":"Procedural and documentation variations in intravenous infusion administration: a mixed methods study of policy and practice across 16 hospital trusts in England","volume":"18","author":"Furniss","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.xphs.2023.09.010_bib0077","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.1038\/s41598-018-25602-6","article-title":"Effectiveness of in-line filters to completely remove particulate contamination during a pediatric multidrug infusion protocol","volume":"8","author":"Perez","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.xphs.2023.09.010_bib0078","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.xphs.2016.09.028","article-title":"Microparticles and nanoparticles delivered in intravenous saline and in an intravenous solution of a therapeutic antibody product","volume":"106","author":"Pardeshi","year":"2017","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2023.09.010_bib0079","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.xphs.2019.02.020","article-title":"Contribution of intravenous administration components to subvisible and submicron particles present in administered drug product","volume":"108","author":"Pollo","year":"2019","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2023.09.010_bib0080","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/jps.23225","article-title":"Particles shed from syringe filters and their effects on agitation-induced protein aggregation","volume":"101","author":"Liu","year":"2012","journal-title":"J Pharm Sci"},{"issue":"158","key":"10.1016\/j.xphs.2023.09.010_bib0081","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2018.0721","article-title":"Do bevacizumab solutions interact with silicone or polyurethane catheters during an infusion through implantable venous access ports?","volume":"16","author":"Tokhadze","year":"2019","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.xphs.2023.09.010_bib0082","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cca.2014.02.031","article-title":"Falsely elevated cyclosporin and tacrolimus concentrations over prolonged periods of time due to reversible adsorption to central venous catheters","volume":"433","author":"Hacker","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"10","key":"10.1016\/j.xphs.2023.09.010_bib0083","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.2012.45.5733","article-title":"Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Schiffer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.xphs.2023.09.010_bib0084","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3109\/0284186X.2013.773072","article-title":"Advantages and disadvantages of peripherally inserted central venous catheters (PICC) compared to other central venous lines: a systematic review of the literature","volume":"52","author":"Johansson","year":"2013","journal-title":"Acta Oncol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492300374X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492300374X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:43:34Z","timestamp":1758361414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235492300374X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S002235492300374X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.09.010","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Survey on Handling and Administration of Therapeutic Protein Products in German and Swiss Hospitals","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}